Eli Lilly (LLY)
(Delayed Data from NYSE)
$887.16 USD
+1.61 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $884.12 -3.04 (-0.34%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$887.16 USD
+1.61 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $884.12 -3.04 (-0.34%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
Zacks News
Pfizer (PFE) Seeks FDA's Emergency Use Nod for COVID Pill
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially in mild-to-moderate COVID-19 patients at increased risk of hospitalizations or death.
3 Big Pharma Outperformers to Watch Out For in the Near Term
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Glaxo (GSK), Vir Intramuscular Sotrovimab Meets Study Endpoint
by Zacks Equity Research
Glaxo (GSK) and Vir announce non-inferiority of intramuscular administration of sotrovimab compared to intravenous administration in reducing hospitalization or death as an early treatment of mild-to-moderate COVID-19.
Biogen (BIIB) Up on New Data From Phase III Studies on Aduhelm
by Zacks Equity Research
Biogen's (BIIB) Aduhelm significantly lowers plasma p-tau-181, a pathological hallmark of Alzheimer's disease, in phase III studies.
Merck (MRK) Inks $1.2B COVID-19 Pill Supply Deal With Japan
by Zacks Equity Research
Japan's government is set to purchase 1.6 million courses of Merck's (MRK) oral pill for COVID-19, molnupiravir, if approved or authorized.
Biohaven (BHVN) Misses on Q3 Earnings, Inks $1.24B Pfizer Deal
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The company signs an agreement with Pfizer, granting the latter ex-U.S. marketing rights to Nurtec ODT.
Radius (RDUS) Q3 Loss Wider Than Expected, Stock Declines
by Zacks Equity Research
Radius (RDUS) reports a year-over-year wider Q3 loss and misses on sales. The company also lowers guidance for lead drug Tymlos.
Pfizer (PFE) COVID Pill Shows Strong Efficacy, Stock Rallies
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially
Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMV
Nektar (NKTR) Q3 Earnings Top, Pipeline Remains On Track
by Zacks Equity Research
Nektar (NKTR) reports mixed third-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.
United Therapeutics (UTHR) Q3 Earnings & Sales Beat, Stock Up
by Zacks Equity Research
United Therapeutics (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.
Novo Nordisk's (NVO) Q3 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected results for Q3. Sales are aided by growth in Diabetes and Obesity Care owing to higher GLP-1 revenues.
PFE vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
Amgen (AMGN) Q3 Earnings Top, Sales View Tightened, Stock Down
by Zacks Equity Research
Amgen (AMGN) beats Q3 estimates for both earnings and sales. It lowers the upper end of the sales guidance for 2021 while raising the earnings range.
Incyte (INCY) Q3 Earnings & Sales Beat, Royalty Revenues Grow
by Zacks Equity Research
Incyte (INCY) beats earnings and sales estimates in the third quarter on higher royalty revenues and increased Jakafi sales.
The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, Sony, American Express and Southern Company
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, Sony, American Express and Southern Company
Top Research Reports for Alphabet, Eli Lilly & Sony
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Eli Lilly and Company (LLY), and Sony Group Corporation (SONY).
Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab
by Kinjel Shah
Several big drugmakers announce third-quarter 2021 earnings. An FDA panel votes in favor of Pfizer's (PFE) COVID-19 vaccine for use in kids 5 to 11 years of age.
Healthcare ETFs in Focus as Q3 Earnings Unfold
by Sweta Killa
The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.
Stock Market News for Oct 27, 2021
by Zacks Equity Research
U.S. stocks continued their winning streak on Tuesday, with the Dow and the S&P 500 closing at record highs for the second straight day as investors digested a slew of earnings reports from some of biggest American corporations.
AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) third-quarter results are expected to reflect the impact of a strong recovery in demand for new drugs. Investors are likely to focus on any update related to guidance.
Eli Lilly (LLY) Q3 Earnings Miss, COVID Drugs Drive Sales
by Zacks Equity Research
Eli Lilly (LLY) reports mixed third-quarter results and raises its 2021 sales forecast.
Home Prices Stay "Lofty;" UPS Beats, Lilly Mixed
by Mark Vickery
The Case-Shiller Home Price Index for August came in at +19.8%, right in-line with what analysts were looking for.
Q3 Earnings Season in Full Swing
by Zacks Equity Research
Q3 Earnings Season in Full Swing